GENERAL FEATURES

• Very easy one-button operation
• Battery-driven
• Optical and acoustic function control
• Automatic switch-off at the end of the therapy period

• 1 In a randomised controlled study on the effect of MAGCELL® ARTHRO for knee arthritis with osteoarthritis level 2.8±0.8 (American College of Rheumatology criteria) at the primary clinical end point (WOMAC total score) median increase of 0.7 P (non-significant) was recorded in the placebo group between T0 and T1 (18 days), yet in the MAGCELL®-group a significant local decrease of 21.8 P. During the study no undesirable incidents or side effects occurred related to therapy.
• 2 The WOMAC individual scores for pain, stiffness and daily activity also resulted in significant local improvements in the MAGCELL®-group compared to a slight median increase (non-significant) in the placebo group. A highly significant result (p < 0.001) in favour of the MAGCELL®-group was recorded for the individual parameter pain reduction compared to the placebo in the difference between the beginning and end of treatment.

• 3 45  MAGCELL® is utilised for pain alleviation and movement stimulation in the case of osteoarthritis